Upgrade to SI Premium - Free Trial

Valeant Pharmaceuticals (VRX): 'A Turnaround For The Ages' - Cantor Fitzgerald

May 8, 2018 2:15 PM
Cantor Fitzgerald analyst Louise Chen reiterated an Overweight rating and $25 price target on Valeant Pharmaceuticals (NYSE: VRX) following Q1 ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments Analyst EPS View

Next Articles